Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE™) at The 62nd Annual Society of Hematology (ASH) Meeting
Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE™) at The 62nd Annual Society of Hematology (ASH) Meeting
NEW HAVEN, Conn., Nov. 30, 2020 (GLOBE NEWSWIRE) --Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present data on KPMW135, a novel CD3 x CD20 bispecific molecule, created by chemically conjugating a CD3- binder directly to rituximab (Rituxan®) using its multi-targeted antibody therapy enhancer (MATE) platform. Data will be presented at the upcoming 62ndAmerican Society for Hematology (ASH) annual meeting, being held in a virtual format December 5- 8, 2020.
亞洲網康涅狄格州紐黑文11月30日電Kleo PharmPharmticals，Inc.是一家目標免疫治療公司，正在開發用於重定向、增強或替換抗體的全合成雙特異性療法。該公司宣佈，將公佈KPMW135的數據。KPMW135是一種新型的CD3 x CD20雙特異性分子，通過使用其多靶向抗體治療增強劑(Mate)平台將CD3結合劑直接與利妥昔單抗(Rituxan®)化學偶聯而成。數據將在即將到來的第62屆美國血液學會(ASH)年會上公佈，該年會將於2020年12月5日至8日以虛擬形式舉行。
Details of the electronic presentation are as follows:
電子演示文稿詳情如下：
Title: KPMW135, a Biosuperior CD3 Bispecific Version of Rituximab Created by a Novel Chemical Conjugation Technology Demonstrates Increased Anti-Tumor Activity by Adding T Cell-Mediated Cytotoxicity Activity to the Existing Mechanisms of Rituximab Number: 3009 Presenter: Christian Vidal, PhD Program: Oral and Poster Abstracts Session: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster III Time and Location: Monday, December 7, 2020: 7:00 a.m. - 3 p.m. PSTPoster Hall (Virtual Meeting)
標題：KPMW135，一種由一種新的化學結合技術創造的生物優勢CD3雙特異性Rituximab版本，通過在Rituximab的現有機制中增加T細胞介導的細胞毒活性而顯示出增強的抗腫瘤活性。Rituximab編號：3009演講者：克里斯蒂安·維達爾，博士項目：口頭和海報摘要會議：625。淋巴瘤：臨牀前化療和生物製劑：Poster III時間和地點：2020年12月7日星期一上午7：00-下午3點PST海報大廳(虛擬會議)
Kleo’s MATE platform enables site-directed chemical conjugation with off-the-shelf therapeutic antibodies to rapidly add or improve functionality to existing therapies. By MATE-ing a CD3 binder to rituximab, an anti-CD20 therapeutic monoclonal antibody used to treat B-cell lymphomas and lymphocytic leukemias, Kleo is able to retain rituximab’s existing mechanisms of action while adding potent and specific activation of T cells to destroy the tumor. In addition tooncologyapplications, the MATE platform is also being used to develop Kleo’s COVID-19 hyperimmune globulin mimic (HGM) therapy.
Kleo的Mate平台能夠與現成的治療性抗體進行定點化學結合，以快速增加或改進現有療法的功能。通過將CD3結合劑與利妥昔單抗(一種用於治療B細胞淋巴瘤和淋巴細胞白血病的抗CD20治療性單抗)配對，Kleo能夠保留利妥昔單抗的現有作用機制，同時增加對T細胞的有效和特異性激活，以摧毀腫瘤。除了腫瘤學應用，Mate平台還被用於開發克利奧的新冠肺炎高免疫球蛋白模擬物(HGM)療法。
About Kleo Pharmaceuticals, Inc. Kleo Pharmaceuticals is a targeted immunotherapy company that develops fully synthetic bispecific therapies to redirect, enhance or replace antibodies. The company was founded on the groundbreaking research of its scientific founder Dr. David Spiegel at Yale University. Kleo’s synthetic immunotherapy platform uses two chemistry-based approaches – antibody-redirecting molecule (ARM) and multi-targeted antibody therapy enhancer (MATE) - that help redirect and stimulate key components of the immune system to eradicate cancer cells and virulent pathogens. Compared to biologic therapies, Kleo’s compounds are smaller and more versatile, allowing for better tumor/tissue penetration, non-immunogenic for improved safety and higher dose levels, more efficient to produce and potentially orally bioavailable. They can be optimized against specified biological targets or combined with existing cell- or antibody-based therapies. Kleo investors include Biohaven Pharmaceutical Holding Company (NYSE:BHVN) and PeptiDream Inc. (Nikkei:PPTDF). For more information, visitwww.kleopharmaceuticals.com.
Kleo製藥公司簡介Kleo製藥公司是一家有針對性的免疫療法公司，開發完全合成的雙特異性療法，以重定向、增強或取代抗體。該公司是在耶魯大學的科學創始人大衞·斯皮格爾博士的開創性研究基礎上創立的。Kleo的合成免疫治療平台使用兩種基於化學的方法-抗體重定向分子(ARM)和多靶點抗體治療增強器(Mate)-這兩種方法有助於重定向和刺激免疫系統的關鍵組件，以根除癌細胞和毒力病原體。與生物療法相比，Kleo的化合物更小，用途更廣，能夠更好地穿透腫瘤/組織，無免疫原性，安全性更高，劑量更高，生產效率更高，可能會有口服生物利用度。它們可以針對特定的生物目標進行優化，也可以與現有的基於細胞或抗體的療法相結合。Kleo的投資者包括生物港製藥控股公司(紐約證券交易所市場代碼：BHVN)和PeptiDream公司(日經市場代碼：PPTDF)。欲瞭解更多信息，請訪問www.kleopPharmPharmticals.com。
CONTACT INFORMATIONLifeSci Advisors(Investors)Irina Koffler646-970-4681ikoffler@lifesciadvisors.com
聯繫信息生活科學顧問(投資者)Irina Koffler646-970-4681ikoffler@lifesciadvisors.com
Susan Kinkead (Media)415-509-3610susan@kinkeadcomm.com
蘇珊·金基德(Media)電話：415-509-3610susan@kinkeadcom.
譯文內容由第三人軟體翻譯。